Table 2 Role of m6A regulator in targeted therapy
From: Emerging roles of m6A RNA modification in cancer therapeutic resistance
Drug | Regulator | Role | Level | Cancer | Target | Effect | Refs. |
|---|---|---|---|---|---|---|---|
Sorafenib | METTL3 | Oncogene | High | HCC | DUXAP8 | Increases DUXAP8 RNA stability | [102] |
Sorafenib | METTL3 | Oncogene | High | HCC | NIFK-AS1 | Upregulates NIFK-AS1 expression | [103] |
Sorafenib | METTL3/14 | Oncogene | High | HCC | SORE | Increases stability of SORE | [104] |
Sorafenib | METTL3 | Suppressor | Low | HCC | FOXO3 | Stabilizes FOXO3 mRNA by YTHDF1 | [105] |
Sorafenib | METTL14 | Suppressor | Low | HCC | HNF3γ | Increases HNF3γ mRNA stability via IGF2BPs | [106] |
Sorafenib | RBM15B | Oncogene | High | HCC | TRAM2 | Increases stability of TRAM2 mRNA | [107] |
Gefitinib | METTL3 | Oncogene | High | LUAD | lncRNA SNHG17 | Increases SNHG17 RNA stability | [108] |
Gefitinib | METTL3 | Oncogene | High | LUAD | ATG5, ATG7 | Upregulates expression of ATG5, ATG7 | [109] |
Gefitinib | KIAA1429 | Oncogene | High | NSCLC | HOXA1 | Increases HOXA1 mRNA stability | [110] |
Gefitinib | FTO | Oncogene | High | NSCLC | ABCC10 | Reduces the YTHDF2-mediated degradation of ABCB10 | [111] |
Gefitinib | FTO | Oncogene | High | NSCLC | MYC | promotes MYC expression | [112] |
Erlotinib | YTHDF2 | Oncogene | NA | LC | TUSC7 | Promotes the degradation of TUSC7 | [113] |
Osimertinib | METTL3 | Suppressor | Low | LUAD | Let-7b | Promotes the pri-Let-7b maturation via HNRNPA2B1 | [114] |
cetuximab | hnRNPA2B1 | Oncogene | NA | CRC | TCF7L2 | Increases stability of TCF7L2 mRNA | [115] |
Cetuximab | METTL3 | Oncogene | High | CRC | miR-100 and miR-125b | Reduces the miR-100 and miR-125b level and export | [116] |
apatinib | METTL3 | Oncogene | NA | GC | P53 | Suppresses p53 activation | [117] |
sunitinib | METTL14 | Oncogene | NA | RCC | TRAF1 | Increases TRAM1 mRNA stability via IGF2BP2 | [118] |
PLX4032 | METTL3 | Oncogene | NA | Melanoma | EGFR | Promotes translation of EGFR | [119] |
crizotinib | METTL3, WTAP | Oncogene | NA | NSCLC | c-MET | Decrease expression of c-MET | [120] |
Olaparib and Rucaparib | FTO, ALKBH5 | Suppressor | Low | FZD10 | Suppresses IGF2BP2-mediated stabilization of FZD10 mRNA | [121] |